-
Basel, February 16, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1. Benefits are most clearly evident in…Reimagine MedicineNeuroscienceMedical InnovationsLiving With Disease
-
One patient’s story reveals the hidden obstacles to better health – and opportunities to help clear them.
Access to HealthcareDisease AwarenessGenetic DiseaseLiving With DiseasePatient Voices -
It’s time to change the conversation. Patient inspired and community led, Sound Up aims to empower people affected by lung cancer in raising the volume to vocally self-advocate.CancerLiving With DiseaseOncologyPatient VoicesSocial Commitment
-
AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1Reimagine MedicineNovartis Gene TherapiesLiving With Disease
-
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular AtrophyReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular AtrophyReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Proposed Public Offering of Common StockReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Pricing of Public Offering of Common StockReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three PatientsReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating ResultsReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating ResultsReimagine MedicineNovartis Gene TherapiesLiving With Disease
-
One patient’s story reveals the hidden obstacles to better health – and opportunities to help clear them.